Sequenom of San Diego has announced an agreement to sell its MassArray system to Metabion.
Terms of the deal were not disclosed.
Metabion of Munich will use the system to monitor its oligonucleotide production while providing Sequenom with a source for oligonucleotides, an element in assay development for genotyping technologies.
Separately, Sequenom said it had agreed to screen DNA samples linked to type 2 diabetes mellitus provided by the US National Institute of Diabetes and Digestive Kidney Diseases, a division of the USNational Institutes of Health.
Sequenom CEO Toni Schuh said the deal would expand the commercial relationship between Sequenom and the National Institutes of Health but he did not offer specifics. Sequenom said it expects current projects from the NIH to generate $500,000 in revenue this year for the company.
In addition, Sequenom also recently launched its 384 SpectroChip, which is designed to increase throughput and reduce the costs associated with the analysis of SNPs.